Tigecycline activity against geographically diverse Acinetobacter spp. displaying multidrug-resistant phenotypes across Europe

Abstract number: P1163

Thornsberry C., Draghi D., Pillar C., Dowzicky M., Sahm D.

Objective:Acinetobacter (AC) is generally a nosocomial pathogen. There are several risk factors among patients that can be associated with increased infection of this organism such as extremely ill patients on a ventilator, those with a prolonged hospital stay, or those with open wounds. In 2006, tigecycline (TIG) was approved in Europe (EU) for treatment of complicated skin and skin structure infections and complicated intra-abdominal infections.

Methods: In total, 104 AC isolates were obtained from 28 hospitals in eleven countries across EU during 2006 to 2007. Isolates were tested centrally by broth microdilution (CLSI M7-A7). TIG activity was analysed according to susceptible (S), non-susceptible (NS), and multidrug phenotypes [MDR; resistance to geqslant R: gt-or-equal, slanted3 agents including cefepime (FEP), ciprofloxacin (CIP), gentamicin (GEN), imipenem (IMI), minocycline (MIN), and piperacillin-tazobactam (PTZ)]. Enterobacteriaceae EUCAST breakpoints (BPs) were applied to all TIG results (BPs do not currently exist for AC). CLSI (M100-S17) BPs were used to interpret all comparators (where applicable).

Results: The most common MDR phenotype was 3-drug R with concurrent R to CIP, GEN, and PTZ (12.5% of all isolates surveyed) followed by 5-drug R with concurrent R to FEP, CIP, GEN, IMI, and PTZ (9.6% of all isolates surveyed).

Conclusions: TIG maintained potent in vitro activity against AC. The TIG MIC90 ranged from 1 to 2 mg/L, regardless of resistance or MDR phenotype. Due to the resistance associated with AC, it is imperative to monitor the susceptibility patterns of this organism against new agents such as TIG.

Session Details

Date: 19/04/2008
Time: 00:00-00:00
Session name: 18th European Congress of Clinical Microbiology and Infectious Diseases
Location: Barcelona, Spain
Presentation type:
Back to top